Once the peptide is cleared, the body's own feedback system steps in and prevents growth hormone from staying elevated all the time
Reported benefits (per available research): Reliably studied for its ability to increase circulating growth hormone (and downstream IGF-1) in both animal models and a human Phase II trial, where it was well tolerated but did not significantly outperform placebo on its primary clinical endpoint Studied in rodent models for effects on bone formation and bone mineral content, including in a glucocorticoid-induced bone-loss model, though this evidence is animal-only and has not been confirmed in controlled human trials Anecdotally and in early/limited research associated with changes in body composition (lean mass, fat mass) and subjective sleep quality, but these claims rely mostly on user reports and small or non-peer-reviewed data rather than robust human clinical trials Known risks and side effects: FDA safety reviewers flagged growth-hormone-secretagogue peptides in this family for potential cardiovascular effects (e.g., increased heart rate, vasodilatory reactions such as flushing and transient hypotension) as part of the rationale for restricting compounding Commonly reported effects include headache, injection-site reactions, and mild fluid retention or bloating tied to growth-hormone-mediated fluid balance changes Because it is sold as an unregulated research chemical outside pharmaceutical manufacturing controls, there is added risk from impurities, mislabeled concentration, and lack of quality assurance, and long-term human safety data remain limited or absent Evidence snapshot: The strongest human evidence is a randomized, double-blind, placebo-controlled Phase II trial (ClinicalTrials.gov NCT00672074) in bowel-resection patients showing ipamorelin was well tolerated but not significantly more effective than placebo for postoperative ileus
A 2022 Cell Reports study (Kim et al.) confirmed sex-dimorphic expression, with distinct patterns and effects in women versus men
Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests
Men Typical range: 200300 g/day Often split into 2 daily injections (e.g., AM and PM) Used for muscle growth , fat loss , and joint/tendon recovery Can tolerate slightly higher doses or longer cycles due to higher natural GH output Women Typical range: 100200 g/day Usually administered once daily (often pre-bed) Preferred for fat loss , skin quality , recovery , and anti-aging More sensitive to peptidesso lower doses often yield similar effects Ipamorelin offers a favorable safety profile for both male and female users, with studies showing similar increases in GH without significant sex-based variance in cortisol or prolactin. Grnlykke et al., Growth Hormone & IGF Research No matter the gender, peptide response can vary based on individual biochemistry, so starting at the lower end and titrating up is often the best approach
Active injury recovery: 4.0 to 6.0mg total daily, or 20 to 30 units
